Published in Physician Law Weekly, October 1st, 2008
Amarin also announced its plans to locate its research and development headquarters in Connecticut, U.S. The new site, which is expected to be operational by year end, will focus primarily on developing Amarin's cardiovascular pipeline, including AMR101 which is entering Phase 3 for hypertriglyceridemia.
Dr. Soni joins Amarin from Pfizer where he held a number of leadership roles in Pfizer Global Research and Development in both experimental medicine and late stage development. He provided clinical leadership to a number...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly